# Model-based development of the secukinumab dosing regimen in psoriasis

Oliver Sander, Achim Guettner, Charis Papavassilis, Michael Looby Ackn.: Secukinumab team, PMX modeling & programming

2016-06-10 PAGE 2016 meeting, Lisbon, Portugal



## Model-based regimen design of secukinumab

- Model-based analysis of phase I / II data allowed design of phase III through prediction of alternative regimens
  Two predicted regimens which had not be tested previously were chosen for phase III
- Efficacy and safety (and model-based predictions) for these regimens were confirmed in phase III
- Secukinumab (Cosentyx) has since been approved for moderate to severe psoriasis in ≥ 60 countries



## Secukinumab as treatment in psoriasis


#### Secukinumab

Human mAb against IL-17A

Neutralizes human IL-17A potently, in vitro and in vivo

New mode of action to intervene in autoimmune diseases

Terminal half-life ~27 days




3 | PAGE meeting 2016 | Oliver Sander | Business Use Only

#### Psoriasis

- Chronic auto-inflammatory skin disease
- Affects ~2-3% of population
- Impacts quality of life






#### **U** NOVARTIS

## Comprehensive phase II program

How to select phase III regimens based on comprehensive phase II?



## Phase II program ↔ modeling

#### Program benefit from modeling

- Bridging across routes, doses, regimens, studies
- Primary endpoint (wk 12) not at steady-state & delay in response
- Optimizing onset, maximum response, maintenance
- Combinatorial optimization of complex regimens not feasible in studies


#### Modeling benefit from program

- Well-behaved endpoint
- Wide dynamic range of inputs and exposure
- Staggered studies allow iterative modeling building and qualification



## Comprehensive phase II program


Iterative modeling allowed confident choice of phase III regimens



**U** NOVARTIS

6 | PAGE meeting 2016 | Oliver Sander | Business Use Only

## Pharmacometric model




- Model alternatives
- Placebo
- Covariates

- Model validation
  - Goodness-of-fit
  - VPCs
  - Prospective prediction

### **U** NOVARTIS


## Model-based design of a new regimen

Phase III: 150mg or 300mg given at weeks 0, 1, 2, 3, 4, 8, 12 +q4wk



**U** NOVARTIS

## Confirmation of predictions in phase III studies



9 | PAGE meeting 2016 | Oliver Sander | Business Use Only





- Model-based analysis of phase I/II data allowed design of phase III through prediction of alternative regimens
  Two predicted regimens which had not be tested previously were chosen for phase III
- Efficacy and safety (and model-based predictions) for these regimens were confirmed in phase III
- Secukinumab (Cosentyx) has since been approved for moderate to severe psoriasis in ≥ 60 countries
- Model allowed many follow-up questions to be addressed such as a best maintenance therapy

**NOVARTIS**